Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human multiple ascending dose intrathecal LTX-002 in adults with amyotrophic lateral sclerosis
2025-522039-33-00Phase 2Authorised
- Sponsor
- Leal Therapeutics
- Start
- Apr 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing LTX-002 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events, Clinical laboratory tests and 3 more. Planned start Apr 2026; status: authorised.
02
Drugs
LTX-002
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2025-522039-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522039-33-00.